News

NEW YORK, NY, May 16, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”).

NEW YORK, NY, May 13, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May

NEW YORK, NY, May 12, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma’s 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.

NEW YORK, NY, May 8th, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.

NEW YORK, NY, April 21, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.

NEW YORK, NY, April 17, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open.

NEW YORK, NY, April 8, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.

NEW YORK, NY, March 27, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET.

NEW YORK, NY, February 27, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET.

NEW YORK, NY, February 12, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).